FDA accepts Bristol-Myers' Opdivo-Yervoy app in lung cancer, but without a speedy review
admin 22nd June 2018 Uncategorised 0Bristol-Myers Squibb’s Opdivo is finally under FDA consideration as a therapy for previously untreated lung cancer, but it will still be a while before it can compete in the key market.
More: FDA accepts Bristol-Myers' Opdivo-Yervoy app in lung cancer, but without a speedy review
Source: fierce